Ryo Ko

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated <i>EGFR</i>

Eisaku Miyauchi, Satoshi Morita, Atsushi Nakamura et al. · Journal of Clinical Oncology · 2022 · 89 citations · Full text

Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease

Hirotsugu Kenmotsu, Kiyotaka Yoh, Keita Mori et al. · Cancer Science · 2019 · 72 citations · Full text

Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease

Hirotsugu Kenmotsu, Tateaki Naito, Keita Mori et al. · Cancer Chemotherapy and Pharmacology · 2015 · 70 citations

Medicine, Pathology, Metronomic Chemotherapy +5

Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure

Shinichi Sasaki, Yasuko Yoshioka, Ryo Ko et al. · Respiratory Investigation · 2015 · 53 citations

Medicine, Active Egfr Mutation, Pathology +8

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients

Ryo Ko, Hirotsugu Kenmotsu, Masakuni Serizawa et al. · BMC Cancer · 2016 · 51 citations · Full text